The European Commission (DG Connect) is looking for industry partners to join the Exscalate4Cov project, seeking to accelerate identification of medicines that can support the fight against COVID-19.

The purpose of this collaboration is to use European supercomputing infrastructure to complement the classical approaches by comparing the signature of the protein of the virus against active molecules that are used in existing databases of compounds. First results based on analysis of publicly available data yielded some promising results which will move to labs for further investigation.

Pharmaceutical companies that have databases of active molecules are invited to make them available to the project (via dedicated non-disclosure agreements) to help enlarging the docking operations in the rapid search of a cure against COVID-19. 

Nine companies already raised their interest (AlfaSigma, Almirall, AstraZeneca, Esteve, Lilly, Merck, Pierre-Fabre, Roche, and Sanofi), and four of them have already completed the formalities to start the collaboration.

Please have a look at this video from the first webinar if you need more information.

Call for Action

Companies interested in exploring this opportunity with DG Connect and Exscalate4CoV are invited to send an email to Magda Chlebus, EFPIA Executive Director, Science Policy & Regulatory Affairs (magda.chlebus@efpia.eu), or to the project coordinator, Andrea Beccari from Dompe (Andrea.Beccari@dompe.com). All expressions of interest will be conveyed to DG Connect who will support further steps and NDA drafting. 


Read more about the project
Science Business